FDA Calls for Nominations as 11 Spots Open on Four Advisory Committees
Posted 04 October 2012 | By
US regulators are calling for the nomination of new members of several prominent advisory committees it uses to formulate non-binding but influential recommendations.
The committees often serve as a pre-review stage for new or controversial products, and the views of its committee members regularly act as a barometer for safety, efficacy and quality concerns.
In a Federal Register notice released 4 October, the US Food and Drug Administration (FDA) said it is aware of 11 vacancies opening up on four advisories committees within the next year.
Its Blood Products Advisory Committee, which reviews many biological products and medical devices, stands to lose the most members, with four leaving by the end of 2013.
Three other committees also stand to lose several members. The Allergenic Products Advisory Committee is set to lose three members, and both the Cellular, Tissue and Gene Therapies Advisory Committee and the Transmissible Spongiform Encephalopathies Advisory Committee are set to lose two members each.
FDA said it is seeking knowledgeable authorities fit for service on the respective committees for four-year terms. Authorities may either self-nominate or nominate other authorities so long as they are able to obtain a current resume or curriculum vitae along with contact information. Nominees should be prepared to disclose all potential conflicts of interest, FDA said.